Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with iron deficiency treatment and hemodialysis products and therapies in the United States and internationally. The company is headquartered in Wixom, Michigan.
| Revenue (TTM) | $69.39M |
| Gross Profit (TTM) | $12.29M |
| EBITDA | $-2.43M |
| Operating Margin | -5.97% |
| Return on Equity | -15.50% |
| Return on Assets | -5.18% |
| Revenue/Share (TTM) | $17.97 |
| Book Value | $8.83 |
| Price-to-Book | 1.02 |
| Price-to-Sales (TTM) | 0.43 |
| EV/Revenue | 0.357 |
| EV/EBITDA | 30.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10.60% |
| Shares Outstanding | $4.03M |
| Float | $3.59M |
| % Insiders | 14.78% |
| % Institutions | 8.52% |
Volatility is currently expanding
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026.
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical received notice from Nasdaq that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's Board of Directors has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply aQua Dialysis with liquid and dry, acid and bicarbonate hemodialysis concentrates and other essential dialysis products.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RMTI and any ticker you trade — then tracks every position and per-strategy win rate.
